Risk intelligence revealing critical blind spots—protecting your budget and reducing exposure to unknowns that delay progress.

  • No AI Use
Research lab bench with equipment

Who Does This Help?

Sponsors, innovators, and their counsel tasked with advancing early-phase pharmaceutical assets toward critical milestones.

GettyImages-2162659885-2048x1080

How We Help

Delivering a bundled suite of human-authored, no–generative-AI, CMC-focused diligence and execution exhibits.

We convert uncertainty into:

  • Verified Proof
  • Quantified Exposure in Dollars
  • Actionable Controls

All engagements operate under NDA, with secure, end-to-end (E2E) encrypted exchange exclusively through Tresorit™.

Why It Matters

  • Surface diligence surprises early—not late
  • Expose liability before capital is committed
  • Strengthen negotiation leverage
  • Improve confidence in cost and valuation assumptions
benefit-4-v3_benefit-4-v3_feature_image (1)

Customizable Services

We conduct comprehensive formulation, process, and manufacturing characterization—defining CQAs, CPPs, C&E matrices, and multivariate interactions.
From this, we deliver:

Change-order-triggers-with-defined

Change-order triggers with defined control strategies

Mechanism-based-risks-with-identified

Mechanism-based risks with identified data and claim gaps

Conversion-of-risks-into-dollars-at-risk

Conversion of risks into dollars-at-risk

Regulatory-exposure-mapped-to-CFR

Regulatory exposure mapped to CFR 210/211

Ranked-failure-points-across-the

Ranked failure points across the execution pathway

No Cost Evaluation

  • Contact CP via email
  • Execute a no-cost NDA
  • Exchange materials securely via Tresorit™ (E2E encrypted)
  • Submit redacted asset details
  • Receive a no-cost risk intelligence exhibit

All collaboration remains confidential, secure, and conducted through encrypted file exchange.

highlight-17_highlight-17_background_image-2-2048x635 (3)